Figure 4From: Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding Kinetics of von Willebrand factor ristocetin cofactor (VWF:RCo) in plasma of the patient with acquired von Willebrand syndrome after replacement therapy with Hemate P. VWF:RCo levels were measured 2 days before and 2, 3 and 4 days after starting high dose intravenous immunoglobulin (Ig) infusion. Back to article page